INTRAHEPATIC ARTERIAL I-131 ANTI-HEPATOCELLULAR CARCINOMA (HCC) MONOCLONAL-ANTIBODY COMBINED WITH HEPATIC-ARTERY LIGATION FOR TREATMENT OF UNRESECTABLE HCC

ZY TANG,ZC ZENG,KD LIU,YQ YU,JZ LU,H XIE

1993-01-01

Abstract:Cytoreduction and sequential resection has provided a new hope for patients with unresectable hepatocellular carcinoma (HCC), but a small proportion of patients have an opportunity for receiving sequential resection. The muitimodality therapy, especially combined with radioimmunotherapy (RAIT), has resulted in better shrinkage of tumor and increased sequential resection rate. Thirty-two patients with surgically verified unresectable HCC have been treated by intrahepatic arterial administration of I-131 anti-HCC monoclonal antibody (Hepama-1 MoAb) combined with hepatic artery ligation. No other treatments were added. Radioimmunoimaging demonstrated that the median tumor/liver ratio was 1.7 at day 5 and increased with the passage of time. Reduction of tumor was observed in 72% (23/32) of patients. After RAIT, sequential resection was performed in 17 patients (53%). The surgical specimens revealed massive necrosis of tumor, but residual cancer cells were found in some specimens. Human anti-murine antibody (HAMA) was determined in 34% (11/32) of patients within 2-4 weeks post-infusion. No marked toxic effects were noted. It is suggested that intra-hepatic arterial I-131 Hepama-1 MoAb is one of the acceptable methods of multimodality treatment for unresectable HCC. Sequential resection is needed to eradicate residual cancer when remarkable tumor shrinkage is achieved.